fax: +34 946 568 732
Steatohepatitis/Metabolic Liver Disease
Article first published online: 27 NOV 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 57, Issue 2, pages 505–514, February 2013
How to Cite
Vazquez-Chantada, M., Gonzalez-Lahera, A., Martinez-Arranz, I., Garcia-Monzon, C., Regueiro, M. M., Garcia-Rodriguez, J. L., Schlangen, K. A., Mendibil, I., Rodriguez-Ezpeleta, N., Lozano, J. J., Banasik, K., Justesen, J. M., Joergensen, T., Witte, D. R., Lauritzen, T., Hansen, T., Pedersen, O., Veyrie, N., Clement, K., Tordjman, J., Tran, A., Le Marchand-Brustel, Y., Buque, X., Aspichueta, P., Echevarria-Uraga, J. J., Martin-Duce, A., Caballeria, J., Gual, P., Castro, A., Mato, J. M., Martinez-Chantar, M. L. and Aransay, A. M. (2013), Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease . Hepatology, 57: 505–514. doi: 10.1002/hep.26052
Potential conflict of interest: Dr. Witte is an employee of Steno Diabetes Center and owns stock in Novo Nordisk.
This research was supported by CYTED 2005-2007 (FIT010000-2005-0013; to A.C. and A.A.M.), La Caixa Foundation 2007-2009 (ID425; to M.L.M.-C. and A.A.M.), Instituto de Salud Carlos III (CIBERehd and PI10/00067; to C.G.-M.) and Fundación Eugenio Rodríguez Pascual (to C.G.-M.); the “Programme Hospitalier de Recherche Clinique” Assistance Publique-Hôpitaux de Paris (AOR 02076), the Commission of the European Communities (Collaborative Project “Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome” HEPADIP, contract LSHM-CT-2005-018734), the European Union Seventh Framework Program (FP7/2007-2013, under grant agreement no. Health-F2-2009-241762, for the project FLIP), the Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country, Saiotek research program (S-PE09UN28 and SA-2010/0025; to X.B. and P.A.); and the Department of Education of the Government of the Autonomous Community of the Basque Country (IT-336-10; to X.B. and P.A.) projects. CIC bioGUNE support was provided from The Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country (Etortek Research Programs 2005-2007) and from the Innovation Technology Department of the Bizkaia County. The Danish part of the study was supported by grants from the Lundbeck Foundation Center for Applied Medical Genomics in Personalized Disease Prediction, Prevention, and Care (www.LuCAMP.org) and from “Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome” (HEPADIP; www.hepadip.org), which is supported by the European Commission as an integrated project under the 6th Framework Program (LSHM-CT-2005-018734). The Basque Biobank is supported by the Basque Foundation for Health Innovation and Research.
- Issue published online: 5 FEB 2013
- Article first published online: 27 NOV 2012
- Accepted manuscript online: 7 SEP 2012 09:02AM EST
- Manuscript Accepted: 6 AUG 2012
- Manuscript Received: 20 MAR 2012
This article has been cited by: